COMMUNIQUÉS West-GlobeNewswire

Veteran Global Health Leader, Dr. Rebecca Martin, Named President of Global Immunization at Sabin
21/07/2025
WASHINGTON, July 21, 2025 (GLOBE NEWSWIRE) -- Renowned global health expert Rebecca Martin, PhD, recognized internationally for her leadership in developing and implementing immunization programs and strengthening [...]
Acentra Health Names Marnie Keogh as Senior Vice President of Marketing
21/07/2025
Proven healthcare marketing leader to drive brand growth and digital engagement in support of the company’s mission to innovate health solutions that accelerate better health outcomes MCLEAN, Va., July 21, 2025 (GLOBE [...]
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
21/07/2025
SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024 , CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage [...]
Foundation for Sarcoidosis Research Sarc Fighter Podcast Surpasses 100,000 Downloads, Amplifying Voices in the Sarcoidosis Community
21/07/2025
CHICAGO, July 21, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is proud to celebrate a major milestone for the FSR Sarc Fighter Podcast , which has officially surpassed 100,000 downloads since [...]
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
21/07/2025
MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the [...]
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
21/07/2025
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
21/07/2025
PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to [...]
Cannara Biotech Inc. annoncera ses résultats financiers du troisième trimestre de l'exercice 2025 le 28 juillet 2025
21/07/2025
MONTRÉAL, 21 juill. 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara » , « la Société » , « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQB : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis [...]
Cannara Biotech Inc. to Announce Fiscal Q3 2025 Financial Results on July 28, 2025
21/07/2025
MONTREAL, July 21, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
21/07/2025
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that [...]
NewGen Subsidiary Signs Memorandum of Understanding with Prominent UAE Real Estate Developer
21/07/2025
The agreement with BNW Real Estate Development LLC positions NewGenDigital to maximize the profitability of its recently acquired plot of land in the UAE Potential net return for the project is estimated to be as high [...]
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®
21/07/2025
Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia Pre-Supplemental New Drug Application meeting with [...]
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
21/07/2025
IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to be shared in an oral [...]
BioCryst to Report Second Quarter 2025 Financial Results on August 4
21/07/2025
RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, [...]
Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation
21/07/2025
NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, [...]
Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia
21/07/2025
CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc., its commercial subsidiary, [...]
Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
21/07/2025
SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market [...]
George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US
21/07/2025
George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US An innovative single pill combination of three [...]
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
21/07/2025
MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic [...]

Pages